GoodRx Holdings, Inc. - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. GoodRx Holdings, Inc. operates a digital healthcare platform providing prescription price comparison, savings codes, subscription programs, and pharmaceutical manufacturer solutions. The company operates as a single segment. As of October 28, 2025, the company had 105.5 million Class A and 234.0 million Class B shares outstanding.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $196.0 million | $195.3 million | $602.1 million | $593.7 million |
| Net Income | $1.1 million | $4.0 million | $25.0 million | $9.7 million |
| Net Income Margin | 0.6% | 2.0% | 4.2% | 1.6% |
| Adjusted EBITDA | $66.3 million | $65.0 million | $205.5 million | $193.2 million |
| Adjusted EBITDA Margin | 33.8% | 33.3% | 34.1% | 32.5% |
| Cash & Equivalents | $273.5 million | $423.8 million | $273.5 million | $423.8 million |
| Debt (Principal) | $496.3 million | $500.0 million | $496.3 million | $500.0 million |
| Operating Cash Flow (9M) | $135.0 million | $139.1 million | $135.0 million | $139.1 million |
Material Changes vs. Prior Period
- Revenue Mix Shift: While total revenue remained flat year-over-year in Q3, the composition shifted significantly. Prescription transactions revenue declined 9% ($13.1 million) due to a decrease in Monthly Active Consumers (MAC) driven by retail pharmacy store closures (e.g., Rite Aid bankruptcy) and volume reductions in integrated savings programs. Conversely, Pharma manufacturer solutions revenue surged 54% ($15.2 million) due to expanded market penetration.
- Profitability Pressure: Net income margin contracted to 0.6% in Q3 2025 from 2.0% in Q3 2024, primarily due to a $5.5 million estimated probable loss accrued for an ongoing consumer privacy class action settlement and higher depreciation/amortization.
- Cost Management: Sales and marketing expenses decreased 7% year-over-year, driven by reduced stock-based compensation and third-party marketing spend. General and administrative expenses increased 25% due to the aforementioned legal accrual.
- Capital Allocation: The company repurchased $61.6 million of Class A common stock in Q3 2025. As of period end, $81.4 million remained available under the $450 million repurchase program.
Guidance, Outlook, and Risks
- Outlook: Management expects the adverse impact on prescription transactions revenue to continue in the near term, estimating a total negative impact of $35.0 to $40.0 million for the full year 2025. However, the company anticipates long-term growth driven by condition-specific subscription programs (launched for erectile dysfunction and hair loss) and pharma manufacturer solutions.
- Regulatory Environment: Significant uncertainty exists regarding the "One Big Beautiful Bill Act" (OBBBA) and potential 100% tariffs on imported pharmaceuticals. The emergence of a government-sponsored platform, "TrumpRx.gov," presents an unclear competitive landscape.
- Legal Contingencies: A $25.0 million settlement for a consumer privacy class action is pending court approval. An additional $5.5 million indemnification loss was accrued in Q3. The company is also defending against state-level litigation in Arkansas and Minnesota regarding discount card compliance.
- Acquisitions: The company acquired VCRx in January 2025 ($30 million) and ScriptDrop in October 2025 ($13.5 million) to enhance prescription delivery and transaction capabilities.
Investor Verification Checklist
- Legal Accruals: Verify the status of the $25.0 million consumer privacy class action settlement and the likelihood of court approval.
- Revenue Trajectory: Monitor the recovery of Monthly Active Consumers (MAC) and the specific impact of the Rite Aid bankruptcy on future transaction volumes.
- Regulatory Impact: Assess the potential revenue cannibalization or competitive threat from the "TrumpRx.gov" platform and new federal healthcare legislation.
- Debt Covenants: Confirm continued compliance with the First Lien Net Leverage Ratio covenant, especially given the recent increase in legal expenses and potential future litigation costs.
- Subscription Growth: Track the adoption rates of the new condition-specific subscription programs to offset declines in the core transaction business.